Disialoganglioside GD2 is a promising target for immunotherapy, primarily expressed by neuroectodermal and epithelial tumor cells. Its role in tumor development includes promoting proliferation, invasion, motility, and metastasis. GD2 is a glycosphingolipid stably expressed on tumor cell surfaces, making it a suitable target for antibodies or chimeric antigen receptors (CARs). Various approaches to GD2 immunotherapy include monoclonal antibodies (mAbs), chimeric and humanized mAbs, combinations with cytokines, toxins, drugs, radionuclides, nanoparticles, and CARs. Vaccines and photoinmunotherapy are also used, along with GD2 aptamers and allogeneic immunocompetent cells. The review discusses the advantages and disadvantages of each method, highlighting future directions for GD2 therapy. Key strategies include optimizing CAR design, combining diagnostic and therapeutic methods, and enhancing the efficacy of mAbs and CARs.Disialoganglioside GD2 is a promising target for immunotherapy, primarily expressed by neuroectodermal and epithelial tumor cells. Its role in tumor development includes promoting proliferation, invasion, motility, and metastasis. GD2 is a glycosphingolipid stably expressed on tumor cell surfaces, making it a suitable target for antibodies or chimeric antigen receptors (CARs). Various approaches to GD2 immunotherapy include monoclonal antibodies (mAbs), chimeric and humanized mAbs, combinations with cytokines, toxins, drugs, radionuclides, nanoparticles, and CARs. Vaccines and photoinmunotherapy are also used, along with GD2 aptamers and allogeneic immunocompetent cells. The review discusses the advantages and disadvantages of each method, highlighting future directions for GD2 therapy. Key strategies include optimizing CAR design, combining diagnostic and therapeutic methods, and enhancing the efficacy of mAbs and CARs.